Ro 24-7429

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Hoffmann-La Roche

Conditions

HIV InfectionsSarcoma, Kaposi

Phase 1

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

CompletedNCT00000760

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 96Updated: 2008-08-04

Phase 2

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

CompletedNCT00002314

Hoffmann-La RocheHIV Infections, Sarcoma, Kaposi

Updated: 2005-06-24